Skip to main content

Formulate

Find pharma jobs. Prep for interviews like no one else can.

Browse

Jobs Companies Drugs Indications Career Advisor About

Insider Intel

Intelligence Hub Therapeutic Areas Contribute Intro Network Salary Explorer For Employers

Legal

Privacy Policy Terms of Service About Our Crawler Content Removal Your Privacy Choices

© 2026 Formulate. Pharma Jobs with Drug Intelligence.

Inmunotek - Jobs & Pipeline | Formulate

Companies
Inmunotek

Inmunotek

Spain - MadridBiotechnology

Website LinkedIn Careers Page

Focus: Inmunotek is a Spanish biotechnology company specializing in allergen extracts and immunotherapy treatments for allergy and immunology indications. The company operates from Madrid with a focused pipeline in allergic rhinitis, mite allergies, and emerging infectious disease vaccines.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

0

About Inmunotek

AI assessmentNot Hiring

No open roles listed right now. Follow Inmunotek to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

10 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

VENOX

Allergy, Insect Venom

N/A

Clinical Trials (1)

NCT06782217Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy

N/A

Help build intelligence for Inmunotek

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep pipeline of 25 programs with 9 in Phase 3, indicating significant clinical advancement and near-term value inflection potential
Focused expertise in allergy and immunology—a stable, underserved market with recurring patient populations and less competitive saturation than oncology
Diversified portfolio spanning allergic rhinitis, mite allergies, UTIs, COVID-19, and COPD suggests exposure to multiple therapeutic breakthroughs

Watch Out For

Currently zero active job openings signals limited near-term hiring momentum or potential organizational constraints
Missing financial data (revenue, R&D spend, cash position, funding history) creates visibility gap on runway stability and growth trajectory

Generated by Claude from Inmunotek's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Uromune

Urinary Tract Infections

N/A

Clinical Trials (1)

NCT04173013Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)

N/A

Allergenic extract

Allergic Reaction

N/A

Clinical Trials (1)

NCT05532566Quercus Ilex and Quercus Robur Allergen Extracts Standardisation

N/A

Allergen extracts

Immune System Diseases

N/A

Clinical Trials (1)

NCT02527122Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts

N/A

Allergenic extract

N/A

Clinical Trials (1)

NCT05533385Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.

N/A

Allergenic extracts

N/A

Clinical Trials (1)

NCT06957496Phleum Pratense and Dactylis Glomerata Allergen Extracts Standardization

N/A

Allergenic Extract

Allergic Reactions

N/A

Clinical Trials (1)

NCT07195929Determination of Blomia Tropicalis Allergen Extract in Prick Test Units

N/A

Clustoid® Max Forte

N/A

Clinical Trials (1)

NCT07427576Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte

N/A

VENOX

Allergy, Insect Venom

N/A

Clinical Trials (1)

NCT06790368Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.

N/A

MV130

Immune Response

Phase 1/2

Clinical Trials (1)

NCT05208060Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

Phase 1/2

MG56 Mannosylated 500 subcutaneous

Phase 2

Clinical Trials (1)

NCT02654223Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy

Phase 2

10 HEP/mL Betula verrucosa allergen extract

Immune System Diseases

Phase 2

Clinical Trials (1)

NCT02527187Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa

Phase 2

MM09 Mannosylated 5.000 subcutaneous

Phase 2

Clinical Trials (1)

NCT02661854Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

Phase 2

3,000 MM09

Allergic Rhinitis

Phase 2/3

Clinical Trials (1)

NCT05641272Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

Phase 2/3

Placebo

Chronic Obstructive Pulmonary Disease (COPD)

Phase 2/3

Clinical Trials (1)

NCT01842360Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)

Phase 2/3

10,000 MG01 +10,000 T521

Rhinitis, Allergic

Phase 3

Clinical Trials (1)

NCT04898283Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Phase 3

Biological vaccine

Bronchospasm; Bronchiolitis

Phase 3

Clinical Trials (1)

NCT01734811Efficacy and Safety Evaluation in Recurrent Wheezing Attacks

Phase 3

10,000 MM09

Rhinitis, Allergic

Phase 3

Clinical Trials (1)

NCT04435990Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Phase 3

Allergen Immunotherapy Extract

Phase 3

Clinical Trials (1)

NCT07348302Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

Phase 3

MM09-MG01

Allergic Rhinoconjunctivitis

Phase 3

Clinical Trials (1)

NCT04874714Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

Phase 3

BACMUNE

Phase 3

Clinical Trials (1)

NCT04452643Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel

Phase 3

Bactek-R

Phase 3

Clinical Trials (1)

NCT04363814Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection

Phase 3

MV140

Urinary Tract Infection Bacterial

Phase 3

Clinical Trials (1)

NCT02543827Evaluation of the Efficacy and Safety of MV140

Phase 3

10,000 MG01 + 10,000 T517

Rhinitis, Allergic

Phase 3

Clinical Trials (1)

NCT04891237Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Phase 3

MM09 allergoid-mannan conjugates subcutaneous

House Dust Mite Allergy

Phase 3

Clinical Trials (1)

NCT05400811Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 25 clinical trials

Top TAs: Respiratory, Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

8 pipeline

Infectious Diseases

2 pipeline

Marketed

Pipeline